Japan						                            
                            
						
 Research Article
												Elevated Serum Antibody Levels against Cyclin L2 in Patients with Esophageal Squamous Cell Carcinoma 						
Author(s): Hideaki  Shimada, Masaaki  Ito, Akiko  Kagaya, Tooru  Shiratori, Mari Kuboshima, Masae  Suzuki, Tian-Ling  Liu, Yoshihiro  Nabeya, Hisahiro  Matsubara, Kazuyuki  Matsushita, Fumio  Nomura, Masaki  Takiguchi and Takaki  HiwasaHideaki  Shimada, Masaaki  Ito, Akiko  Kagaya, Tooru  Shiratori, Mari Kuboshima, Masae  Suzuki, Tian-Ling  Liu, Yoshihiro  Nabeya, Hisahiro  Matsubara, Kazuyuki  Matsushita, Fumio  Nomura, Masaki  Takiguchi and Takaki  Hiwasa             
						
												
				 Cyclin L2 (CCNL2) (Acc. No.: NM_030937) was detected as a tumor antigen of esophageal squamous cell carcinoma (SCC) by serological identification of antigens by recombinant cDNA expression cloning (SEREX). Serum anti-CCNL2 antibodies were detected by enzyme-linked immunosorbent assay more frequent in patients with esophageal SCC than in healthy donors (32% and 15%, P<0.01). An AlphaLISA further confirmed the significant difference in serum antibody levels between the patients and healthy donors using a different set of serum specimens. The expression levels of CCNL2 mRNA detected by reverse transcription polymerase chain reaction were higher in esophageal SCC tissues than those detected in adjacent normal esophageal tissues. We then analyzed for biological function by the transient transfection of CCNL2 expression plasmids into ras-NIH3T3 mouse fibrobla.. Read More»
				  
												DOI:
												 10.4172/1948-5956.1000326 
																	  
Cancer Science & Therapy received 5332 citations as per Google Scholar report